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2Interventional Cardio-Angiology Unit, Villa Maria Cecilia Hospital, Cotignola (RA), ItalyLarge randomized trials comparing endarterectomy
(CEA) vs Best Medical Therapy (BMT) have convinc-
ingly demonstrated that surgery significantly reduces
the long-term risk of subsequent stroke from severe
carotid artery stenosis in symptomatic and asymptom-
atic patients.1e4 Nowadays surgery remains the
standard of care for patients with severe obstructive
carotid artery disease but carotid artery stenting
(CAS) has progressed in recent years, and is now chal-
lenging CEA as an alternative for stroke prevention.
During the last decade single center experiences have
been collecting data on the efficacy of CAS, but only
few randomized trials comparing CAS vs. CEA have
been published. The Cochrane database reports a total
of 1269 patients with carotid artery stenosis that
were treated in five randomised trials (LEICESTER
2001, WALLSTENT 2001,CAVATAS 2001, KENTUCKY
2001, SAPPHIRE 2004), reporting a heterogeneity of
outcome, no significant difference in the major risks
of treatment, and the wide confidence intervals indi-
cate that it is not possible to exclude a difference in
favour of one treatment.5
At this moment there is a lot of interest in the
results of the on-going trials, and two of these,
EVA-3S6 and SPACE,7 have just published their data.
These two trials enrolled a total of 1727 patients
with symptomatic carotid stenosis but are not able
to clarify the dilemma. Both trials were stopped: the
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arm, and the SPACE trial for the lack of adequate
funding that made impossible to enrol 2500 patients,
needed to have an 80% power statistical analysis.
The EVA-3S had already been stopped in 2003,
because of the very high percentage of stroke (20%)
of the unprotected procedure. The stroke-rate
dropped after the re-start of the trial with an embolic-
protection-device but still with a high rate of neuro-
logical complications (9.6%).
In the SPACE trial the results in patients treated
with CAS were better (6.84%) but the difference of
0.51% (90% CIe1.89 to 2.91) between the two arms
did not allow to confirm the non-inferiority hypothe-
sis of CAS versus CEA.
Notably in the latter study only 27% of the CAS
patients received a protection device.
The results of both trials are discouraging espe-
cially for the CAS arm: although the patients were
symptomatic, the 30-day stroke and death rates are
not similar to those of contemporary CEA and CAS
publications and registries.
A possible explanation for these results probably
lies in the technical expertise required for interven-
tional physicians to join the trials (EVA-3S: 12 CAS
or 35 stenting procedures in the supra-aortic trunks,
5 of which had to be CAS; SPACE: 25 successful ca-
rotid percutaneous transluminal angioplasties or stent
procedures).
Moreover, the EVA-3S protocol stated that inter-
ventional physicians who did not fill these require-
ments were nevertheless accepted, provided that the
procedures were performed under the supervision
of an ‘‘experienced tutor’’ defined as ‘‘a clinician
who qualified to perform stenting in this study’’.rved.
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ventionalist’’ a physician with an expertise of either
12 CAS or 35 stenting procedures of the supra-aortic
trunks, 5 of which CAS? Furthermore, is this interven-
tionalist so experienced that he can act as a proctor for
another physician willing to participate to a trial com-
paring CAS versus CEA in patients suffering from
TIA or minor stroke due to severe carotid stenosis?
As difficult as it is to say, we must admit that both
EVA 3S and SPACE didn’t match an acceptable level
of physician training and credentialing. The conse-
quences of this technical bias on the reported CAS re-
sults are left to the scientific community’s evaluation.
We strongly believe that at this moment the real ap-
plicability of CEA and CAS is very different. CEA has
been widely performed during the last thirty years by
experienced and fully trained vascular surgeons,
while CAS is a recently emerged treatment, that can-
not yet be generalized.
A correct learning curve for this procedure is man-
datory and cannot be reached with 12 cases or with 35
generic PTA or stenting procedures of supraortic ves-
sel as suggested by EVA 3S trial. Moreover, carotid
stenting requires specific expertise that is not acquired
with 25 procedures as reported in the SPACE trial.
To this regard, a recently published Consensus
Document8 among all the specialists involved in the
CAS scenario, suggested that the minimum recom-
mended training to achieve competence is at least
150 procedures of supra-aortic vessel engagement
(during diagnostic as well as interventional proce-
dures), 100 of which as primary operator, or at least
75 carotid stenting procedures, 50 of which as primary
operator within two-years.
We are far away from the resolution of the dilemma
and up to now, the analysis of more than 2900 patients
treated within the published trials have not shown
a clear evidence of CAS inferiority to CEA.
This number will increase in the future years with
the ongoing trials CREST, ACST 2, TACIT, ICSS, and
hopefully when the results of these trials will be dif-
fused we will reach a better knowledge of the value
and efficacy of CAS.The potential technical gap related to CAS has to be
overcome by reliable programs for physician training
and credentialing.
CAS is a procedure that can not be easily standard-
ized: in clinical practice we have learned that a patient
with a specific carotid plaque and supra-aortic anatomy
needs a tailored procedure and additional expertise.
A randomized trial comparing CEA and CAS is
needed, where both rigorous standard of practice and
technical skills will be required and where the use of
an embolic protection device will be mandatory.
References
1 European Carotid Surgery Trialists’ Collaborative Group. Rando-
mised trial of endarterectomy for recently symptomatic carotid
stenosis: final results of the MRC European Carotid Surgery Trial
(ECST). Lancet 1998;351:1379e1387.
2 North Am Symptomatic Carotid Endarterectomy Trial Collabora-
tive Group. The final results of the NASCET trial. N Engl J Med
1998;339:1415e1425.
3 Executive Committee for the Asymptomatic Carotid Atheros-
clerosis Study. Endarterectomy for asymptomatic carotid artery
stenosis. JAMA 1995;273:1421e1428.
4 MRC asymptomatic carotid surgery trial (ACST) collaborative
group. Prevention of disabling and fatal strokes by successful
carotid endarterectomy in patients without recent neurological
symptoms: randomised controlled trial. Lancet 2004;363:
1491e1502.
5 COWARD LJ, FEATHERSTONE RL, BROWN MM. Safety and efficacy of
endovascular treatment of carotid artery stenosis compared
with carotid endarterectomy: a Cochrane systematic review of
the randomized evidence. Stroke 2005 Apr;36:905e911.
6 MAS JL, CHATELLIER G, BEYSSEN B, BRANCHEREAU A, MOULIN T,
BECQUEMIN JP et al. EVA-3S Investigators. Endarterectomy versus
stenting in patients with symptomatic severe carotid stenosis.
N Engl J Med 2006 Oct 19;355(16):1660e1671.
7 SPACE Collaborative Group, RINGLEB PA, ALLENBERG J,
BRUCKMANN H, ECKSTEIN HH, FRAEDRICH G, HARTMANN M et al. 30
day results from the SPACE trial of stent-protected angioplasty
versus carotid endarterectomy in symptomatic patients: a ran-
domised non-inferiority trial. Lancet 2006 Oct 7;368(9543):
1239e1247.
8 CREMONESI A, SETACCI C, BIGNAMINI A et al. Carotid Artery Stenting.
First Consensus Document of the ICCS-SPREAD Joint Committee.
Stroke 2006;37:2400e2409.
Accepted 7 November 2006
Available online 22 November 2006Eur J Vasc Endovasc Surg Vol 33, January 2007
